Clinical Trials Logo

Urinary Tract Infections clinical trials

View clinical trials related to Urinary Tract Infections.

Filter by:

NCT ID: NCT02650518 Recruiting - Clinical trials for Catheter-Related Infections

Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections

CARCUTI
Start date: December 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Hypothesis: A short course (3-5 days) of antibiotic therapy (experimental arm) is as safe and effective as a long course of antibiotic therapy for the treatment of catheter-associated urinary tract infections.

NCT ID: NCT02641015 Completed - Clinical trials for Urinary Tract Infections

Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)

RESCUING
Start date: December 2015
Phase: N/A
Study type: Observational

A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)

NCT ID: NCT02640326 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

McMaster Catheterization for Thoracoscopic Surgery Study

UCATh
Start date: December 1, 2018
Phase: N/A
Study type: Interventional

It is common practice to insert a Foley catheter into the bladder to drain urine during and after a lung resection. Recently, there has been increasing interest in the potential risks associated with this catheterization, particularly with regard to infection. As thoracic surgery adopts minimally invasive surgical techniques, the need for urinary catheterization during surgery is being questioned since these less invasive surgeries are known to result in less post-operative acute pain, shorter length of stay, and other outcomes that tend to decrease overall anesthetic needs for this patient population. Thus, there is a need to investigate whether patients who have had a minimally invasive lung resection truly need the Foley catheter at all. This will be achieved by assigning patients to either an experimental no-catheter group or the standard of care routine urinary catheter group to determine if patients with no catheter experience different rates of complications. This pilot study will primarily determine if there is a difference in post operative urinary complications between the groups. It is hoped that this study will definitively determine whether a Foley urine catheter is a necessary procedure in the course of a minimally invasive lung resection.

NCT ID: NCT02639520 Completed - Clinical trials for Urinary Tract Infection

Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

Start date: December 2015
Phase: Phase 3
Study type: Interventional

To demonstrate non-inferiority of a non-antibiotic therapy with CLR versus an antibiotic treatment with fosfomycin trometamol in women suffering from acute lower uUTIs as measured by the proportion of patients who received an additional antibiotic treatment for acute lower uUTIs during the trial.

NCT ID: NCT02637986 Withdrawn - Clinical trials for Urinary Tract Infections (UTIs)

The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy

Start date: November 7, 2022
Phase: N/A
Study type: Interventional

Background: Urinary tract infections (UTIs), the most common infection in pregnancy,are associated with several maternal and fetal complications, including maternal septic shock, preterm labor, intrauterine growth restriction and intrauterine fetal death. Thus, the prevention of UTIs in pregnancy is a very important goal. Several studies have suggested that alterations in the vaginal flora were associated with recurrent UTIs, and probiotic administrations may have a role in preventing those infections. Nevertheless, this has never been tested in pregnant women.

NCT ID: NCT02623179 Completed - Clinical trials for Urinary Tract Infections-UTI

Conventional and Molecular Diagnostic Method for Patients With Suspected UTI

Start date: January 15, 2016
Phase: N/A
Study type: Interventional

In this protocol, the investigators are examining the use of a novel pathogen testing technology and method of identification of antibiotic susceptibility against the conventional C & S testing for patients with both complicated and uncomplicated UTIs. The investigators will examine the two modes in terms of objective patient related outcomes, i.e. 1) diagnostic accuracy and degree of detail of final analysis; 2) time to resolution of symptoms; 3) quality of life as defined by particularly symptomology and "bothersomeness" of the symptoms; and 4) overall cost.

NCT ID: NCT02598362 Completed - Clinical trials for Urinary Tract Infection

Pharmacokinetics of Ciprofloxacin in Pediatric Patients

Start date: April 2015
Phase: Phase 4
Study type: Interventional

Measuring serum and urine concentrations of ciprofloxacin after IV and oral administration in children aged 3 months - 17 years who are treated for urinary tract infections.

NCT ID: NCT02591901 Completed - Neurogenic Bladder Clinical Trials

Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)

PReSuTINeB
Start date: April 6, 2018
Phase: Phase 2
Study type: Interventional

Due to the damage caused to the spinal cord, patients with spinal cord injury, cauda equina syndrome, multiple sclerosis and transverse myelitis may encounter loss of bladder function, which in turn can lead to a debilitating and costly complication: Urinary Tract Infections (UTIs). Given that these patients with loss of bladder function do not normally feel symptoms like pain - as would be the case in otherwise healthy persons - there is no clear agreement among experts on which signs and symptoms are indicative of a UTI. Although strong evidence is lacking, antibiotics have been widely used for prevention of recurrent UTIs in patients with loss of bladder function. However, this approach is now being questioned as antibiotic resistance has become a world-wide health concern. Policy makers recently stressed the importance of research into alternative preventative treatments. The use of immunotherapy is one such an alternative approach, which works by stimulating the body's immune system. One of these immunotherapy is a Uro-Vaxom® oral capsule which consists of inactivated traces of the bacteria that normally cause at least 83% of UTIs in patients with loss of bladder function. Previous studies show that Uro-Vaxom® resulted in a significant reduction of UTIs in otherwise healthy patients, as well as being safe to use. Before investigating the effects of this promising new immunotherapy, this proposed study aims to clarify two crucial issues. First, after reviewing the literature and appraising patients', carers' and healthcare professionals' experiences, the aim is to reach an agreement on how to measure a symptomatic UTI in patients with loss of bladder function that results from a spinal cord lesion. Second, using Uro-Vaxom® Investigators aim to conduct a smallscale, placebo-controlled trial with 48 participants to investigate the feasibility of carrying out a larger trial on prevention of symptomatic UTI in such patients.

NCT ID: NCT02585115 Completed - Clinical trials for Urinary Tract Infections

Diagnostic Accuracy of Point of Care Test of First Voided Urine Compared to Midstream Voided Urine in Primary Care

Start date: October 2015
Phase: N/A
Study type: Observational

The aim of this study is to determine if sampling technique of urine affects diagnostic modalities in primary care. Furthermore it aims to determine if there is difference in the accuracy of the point-of-care test, when the urine sample is stored at room-temperature and analyzed later in the day.

NCT ID: NCT02572895 Recruiting - Clinical trials for Urinary Tract Infections

Cranberry Extract and Urinary Infection Prevention: a Clinical Trial

PACCANN
Start date: August 2015
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent urinary tract infection (UTIs), efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of Proanthocyanidins (PACs), compared to a control dose quantified and standardized to 2 mg/day of PACs on mean number of new UTIs during a 6-month follow-up period.